***Background.*** Peramivir is a parenteral neuraminidase inhibitor (NAI) with potent in vitro activity against all influenza sub-types. Although oseltamivir is widely used for the treatment of influenza, a need still exists for an effective and safe parenteral treatment. Peramivir has been studied as a single dose treatment in acute uncomplicated influenza

***Methods.*** Subjects presenting within 48 hours of symptom onset of acute uncomplicated influenza were enrolled in four randomized, double-blind placebo-controlled trials of single dose peramivir (IV or IM doses ranging from 150-600 mg). Bioequivalence studies demonstrated equivalent systemic exposure for IM and IV administration. Subjects recorded severity of influenza signs and symptoms in a diary. Serial viral titers were measured from nasopharyngeal swabs. An integrated analysis of efficacy was performed.

***Results.*** Of the 1131 subjects enrolled, 1028 subjects with influenza confirmed by laboratory test were included in the integrated efficacy analysis. Key clinical and virologic outcomes are shown:

Subgroup analyses by region, age, gender, race, smoking status, influenza virus subtype, symptom duration at baseline, and severity of illness showed consistency in demonstrating that peramivir was generally superior to placebo across the subgroups studied.

                                                                                                     Peramivir                                                      
  ---------------------------------------------------------------------------- --------------------- --------------------- -------------------- ------------------- -------------------
  Time to alleviation of symptoms, median, hrs (95% CI)                        107.4 (95.8, 115.9)   114.1 (95.2, 145.5)   84.1 (68.6, 102.0)   79.4 (69.3, 92.0)   87.6 (79.3, 95.0)
  Time to resolution of fever, Median, hrs (95% CI)                            47.2 (43.3, 55.6)     51.7 (43.5, 61.7)     39.1 (32.3, 41.0)    38.4 (31.5, 43.3)   40.8 (39.0, 42.7)
  Time to resumption of usual activities, median, days (95%CI)                 10.0 (8.0, 10.0)      10.0 (9.0, 12.0)      8.0 (7.0, 9.0)       6.0 (6.0, 7.0)      8.0 (7.0, 9.0)
  Viral titer: change from baseline at 48 hrs, mean log~10~ TCID~50~/mL (SD)   -1.43 (1.31)          -1.84 (1.43)          -1.94 (1.32)         -1.97 (1.52)        -1.91 (1.38)

***Conclusion.*** Consistent, significant, dose ordered improvements were seen in each endpoint. The treatment effect size is similar to that reported for other NAIs.
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